Best deals to access real time data! |
Canadian Level 1 + USA
Monthly Subscription
for only
|
CHART Trader
Monthly Subscription
for only
|
Big Cap Pro
Monthly Subscription
for only
|
VAT not included
|
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Immuron Ltd | IMRN | NASDAQ | Depository Receipt |
Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded ![]() |
|
---|---|---|---|---|---|---|---|---|
0.00 | 0.0% | 3.8682 | 0.00 | 0.00 | 0.00 | 3.8682 | 09:29:40 |
Bid Price | Ask Price | Spread | Spread % | News | |
---|---|---|---|---|---|
3.75 | 4.14 | 0.39 | 9.42% | - | - |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | 0.00 | USD |
Immuron Financials
Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | |
---|---|---|---|---|---|
17.10M | 4.42M | -3.01M | -0.90 | - | 4.42M |
Dividends Per Share | Dividend Yield | ||||
---|---|---|---|---|---|
- | - | 0.00% | - | - |
News Immuron
Date | Time | Source | Heading |
---|---|---|---|
11/21/2019 | 07:00 | GlobeNewswire Inc. | Immuron Plans Phase 3 trial for IMM-124E to Prevent.. |
11/21/2019 | 06:05 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
11/06/2019 | 06:12 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
11/06/2019 | 06:09 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
11/04/2019 | 11:30 | GlobeNewswire Inc. | Immuron Receives AUD $0.53M R&D Tax Concession Refund |
11/04/2019 | 06:16 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
10/29/2019 | 06:05 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
IMRN Historical
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products. |